Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

[News]

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

More... (http://www.news-medical.net/news/20160316/Halozyme-Therapeutics-doses-first-patient-in-Halo-301-7c-Pancreatic-study.aspx)